Navigation Links
Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
Date:10/17/2011

TARRYTOWN, N.Y., Oct. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) (the "Company") announced that it intends to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2016 in a private placement.  The notes will be offered by the initial purchaser only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.  The Company also intends to grant to the initial purchaser a 13-day option to purchase up to an additional $60 million aggregate principal amount of notes on the same terms and conditions.

The Company intends to use a portion of the proceeds of the offering, together with the proceeds from the warrant transactions, to fund the cost of the convertible note hedge transactions in connection with the offering, each as described below.  The Company intends to use the remaining net proceeds for general corporate purposes.

The notes will be general senior unsecured obligations of the Company.  The notes will be convertible, subject to certain conditions, into cash, shares of common stock of the Company, or a combination of cash and stock, at the Company's option.  The notes will mature on October 1, 2016 unless previously repurchased or converted in accordance with their terms prior to such date.  The interest rate, conversion rate, conversion price and other terms of the notes will be determined at the time of the pricing of the offering.

In connection with the offering of the notes, the Company plans to enter into privately negotiated convertible note hedge and warrant transactions with counterparties that may include the initial purchaser and/or its affiliates.  The convertible note hedge transactions will cover, subject to customary anti-dilution adjustments, the number of shares of the Compa
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
2. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
3. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
4. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
5. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
6. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
7. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
8. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
9. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
10. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
11. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 The U.S. Department of Labor ... University Edwardsville as part of the Trade Adjustment Assistance ... is co-administered by the Department of Labor and Department ... Labor Thomas E. Perez and Secretary of Education Arne ... training grants to nearly 270 colleges across the country. ...
(Date:9/30/2014)... September 30, 2014 Applying a well-known optical ... at Harvard University has demonstrated the ability to ... work that holds promise for making future, flexible ... the sides of next-gen rocket ships and spacecraft ... passes through oil in water, it becomes iridescent, ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... trends and segments with highest potential revenues Do ... Visiongain,s updated report gives you revenue predictions for ... ahead. For those therapies you find financial data, ... new analysis you get sales forecasts to 2024 ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Proove ... medicine, is excited to announce a new genetic test ... The Proove Pain Perception Test will provide physicians ... and why pain tolerance levels are stratified between individuals. ... identify whether a person has a genetic predisposition that ...
Breaking Biology Technology:U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4Taking thin films to the extreme 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... Principle Reached to Terminate Marketing Agreement with Triax ... on Most Favorable Terms, NAPA, Calif., May 15 ... company engaged in the development,of technologies that target the ... quarter ended March 31, 2008 and an agreement in,principle ...
... May 15 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) ... & Renshaw 5th Annual Global Healthcare Conference on,May 19, ... and at the 2008 UBS,Global Generic and Specialty Pharmaceuticals ... time (5:00 a.m. EDT). The presentations will,be web cast ...
... Mass., May 15 Hologic, Inc. (Nasdaq:,HOLX) today ... be,presenting at the Citigroup Investment Research Global Healthcare,Conference ... the Hilton Hotel in New York,NY., Interested ... audio webcast of,Hologic,s investor presentation on Thursday, May ...
Cached Biology Technology:Senetek PLC Reports First Quarter 2008 Financial Results 2Senetek PLC Reports First Quarter 2008 Financial Results 3Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 2Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 3
(Date:9/30/2014)... suite of perilous threats in today,s ocean. From ... change, fragile coral ecosystems are disappearing at unprecedented ... species of corals surrounding the island of Moorea ... their tropical environment: coral guard-crabs. New research from ... Station scientist Seabird McKeon and the museum,s predoctoral ...
(Date:9/30/2014)... 2014 Winners of The Economist,s prestigious Innovation ... to take place at the JW Marriott Hong Kong on Friday, ... will share their experiences and the lessons those hold for others. ... innovation over the past decade, will be presented at a ceremony ... summit. It will be the first time the ceremony has come ...
(Date:9/29/2014)... new study confirms that the exposure to tar tended ... of regular cigarettes. Similarly, exposure to nicotine tended ... popular type of cigarette in several countries around the ... certain toxic chemicals in the smoke of these cigarettes ... lower levels of chemicals in the smoke are not ...
Breaking Biology News(10 mins):Smithsonian scientists discover coral's best defender against an army of sea stars 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Slim cigarette smokers not exposed to more harmful chemicals 2
... activity resource, a personal assistant - computers are ubiquitous. ... lot to be desired: they rapidly become obsolete, typically ... components that are difficult to recycle. Moreover, they consume ... release of CO2 into the atmosphere. Employees at ...
... a vital element not only for plants but also ... have been faced with a growing shortage of this ... been steadily increasing. It is therefore high time to ... task, because phosphorus cannot be replaced by any other ...
... a biological marker that may help to identify ... rapid-acting antidepressant. The brain signal, detectable by noninvasive ... mechanism, which are vital for drug development, say ... is among the latest of several such markers, ...
Cached Biology News:Eco-computer with a natural wood look 2Using wastewater as fertilizer 2Using wastewater as fertilizer 3Brain signal IDs responders to fast-acting antidepressant 2Brain signal IDs responders to fast-acting antidepressant 3Brain signal IDs responders to fast-acting antidepressant 4Brain signal IDs responders to fast-acting antidepressant 5Brain signal IDs responders to fast-acting antidepressant 6
Rabbit polyclonal to Factor IX ( Abpromise for all tested applications). entrezGeneID: 2158 SwissProtID: P00740...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Chicken polyclonal to Thioredoxin domain containing 9 ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez Gene ID: 10190 Swiss Protein ID: O14530...
Biology Products: